缺铁:在心力衰竭患者中,缺铁是一种无声的威胁,心脏衰竭患者的排气分数减少
Nitin Sarate1, Rahul Sonawane1, Vinayak Pai1
1Department of Medicine, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, IND.
Cureus
|March 6, 2024
概括
缺铁显著增加死亡率和不良症状,如心力衰竭的呼吸障碍与减少喷射率 (HFrEF) 患者. 这一发现突显出缺铁是HFrEF管理中的关键预后因素.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 铁缺乏症是心力衰竭患者的常见和显著的并发症,心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭
- 铁缺乏对HFrEF临床结果,死亡率和生理参数的确切影响需要进一步调查.
研究的目的:
- 评估HFrEF患者铁缺乏症的临床特征.
- 评估铁缺乏对该患者群体的发病率和死亡率的影响.
主要方法:
- 一项前性队列研究,涉及印度爱德华国王纪念医院的371名HFrEF患者.
- 进行了全面的临床和实验室评估,包括铁缺乏症,症状,并发症和血液学参数的评估.
- 使用统计分析来确定缺铁组和补铁组之间的相关性和显著差异.
主要成果:
- 50%的HFrEF参与者 (n=185) 缺铁;其中80%的人也患有贫血,而补铁患者的比例为43%.
- 缺铁与死亡率增加有显著的相关性 (p=0.048) 和与呼吸障碍严重程度有强烈的正相关性 (p=0.026).
- 血红蛋白,血清铁,铁素,铁的总结合能力和转激素和度的显著差异被观察到,但左心室喷射小部分没有.
结论:
- 缺铁是HFrEF的关键预后因素,而不仅仅是并发症.
- 它与不良结果有关,包括贫血,,呼吸困难,关静脉压力升高,死亡率增加.
- 解决铁缺乏症对于改善HFrEF患者的临床轨迹和结果至关重要.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
05:08Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
Published on: January 31, 2022
4.6K
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:22Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338